Sihuan Pharmaceutical Holdings Group Ltd. , A China Military Spin-Out, Sees Ebola Drug NDA By Year-End

In a call with investors, Sihuan Pharma announced its newly acquired Ebola treatment, JK-05, could file for China approval by year-end if the drug is fast-tracked under CFDA green-light rules. The company cited the ten-year-old history of the SARS vaccine as an example of regulatory efficiency. Sihuan acquired the drug from China's Academy of Military Medical Sciences (AMMS). Because Sihuan was spun out of AMMS in 2001, it retains close ties with the military drug development organization.

Help employers find you! Check out all the jobs and post your resume.